canakinumab

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Systemic Juvenile Idiopathic Arthritis

Conditions

Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers

Trial Timeline

Nov 3, 2014 → Aug 31, 2018

NCT ID

NCT02334748

About canakinumab

canakinumab is a phase 3 stage product being developed by Novartis for Systemic Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02334748. Target conditions include Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers.

What happened to similar drugs?

10 of 20 similar drugs in Systemic Juvenile Idiopathic Arthritis were approved

Approved (10) Terminated (4) Active (7)

✅Baricitinib + CyclophosphamideEli LillyApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅EfalizumabMerckApproved

✅AmbrisentanGilead SciencesApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04476706	Pre-clinical	Completed	—	—	Cytokine Release Syndrome in COVID-19-induced Pneumonia
NCT04795466	Phase 2	Terminated	Oct 28, 2021	Mar 7, 2024	Mild Cognitive Impairment
NCT04717635	Phase 3	Completed	Mar 30, 2021	Apr 16, 2025	Adult Onset Still's Disease
NCT04239157	Phase 2	Recruiting	Aug 25, 2020	Dec 31, 2026	Chronic Myelomonocytic Leukemia
NCT02980263	Phase 2	Withdrawn	Nov 15, 2016	Nov 30, 2017	Kawasaki Disease
NCT02756650	Phase 2	Completed	Jun 23, 2016	Jan 31, 2019	Behcet Disease
NCT02396212	Phase 3	Completed	May 7, 2015	Aug 1, 2018	Systemic Juvenile Idiopathic Arthritis
NCT02334748	Phase 3	Completed	Nov 3, 2014	Aug 31, 2018	Systemic Juvenile Idiopathic Arthritis
NCT01303380	Phase 2	Completed	Mar 1, 2011	Jul 1, 2014	Mevalonate Kinase Deficiency
NCT01276522	Phase 2	Completed	Jan 1, 2011	Dec 1, 2011	Schnitzler Syndrome
NCT01148797	Phase 2	Completed	Dec 1, 2010	—	Colchicine Resistant/Intolerant Familial Mediterranean Fever
NCT01170936	Phase 2	Completed	Jul 1, 2010	Dec 1, 2011	Urticaria
NCT01088880	Phase 2	Completed	Apr 1, 2010	Aug 1, 2011	Familial Mediterranean Fever
NCT00991146	Phase 3	Completed	Oct 1, 2009	Feb 1, 2012	Cryopyrin-associated Periodic Syndromes
NCT00891046	Phase 3	Completed	Sep 1, 2009	Dec 1, 2014	Systemic Juvenile Idiopathic Arthritis
NCT00927810	Phase 2	Completed	Jun 5, 2009	Aug 4, 2010	Gouty Arthritis
NCT00770601	Phase 3	Terminated	Jan 26, 2009	Feb 17, 2011	NOMID
NCT00554606	Phase 2	Completed	Oct 11, 2007	Aug 13, 2009	Rheumatoid Arthritis
NCT00487708	Phase 2	Completed	Jan 1, 2005	Jul 1, 2008	NALP3 Mutation

Competing Products

20 competing products in Systemic Juvenile Idiopathic Arthritis

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 2	35
E6742	Eisai	Phase 1/2	32
KHK4827	Kyowa Kirin	Phase 1	29
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Cyclophosphamide	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29